The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).
 
Thomas J. Herzog
Leadership - GOG Foundation
Consulting or Advisory Role - Aravive; AstraZeneca; Caris MPI; Clovis Oncology; Eisai; Epsilogen; GlaxoSmithKline; Johnson & Johnson; Merck; Mersana; Roche/Genentech; Seagen
 
John L. Hays
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deciphera; Ipsen; Merck; Mersana; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Merck; Tesaro
 
Joyce N. Barlin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; OncoC4
Speakers' Bureau - AstraZeneca; Clovis Oncology; Merck
 
Joseph Buscema
Research Funding - US Oncology Network
 
Noelle Gillette Cloven
Consulting or Advisory Role - Toray Industries
 
Lynn R. Kong
No Relationships to Disclose
 
Nidhi Kumar Tyagi
No Relationships to Disclose
 
Grainger Lanneau
No Relationships to Disclose
 
Beverly J Long
No Relationships to Disclose
 
Robert L. Marsh
No Relationships to Disclose
 
Shelly Marie Seward
Consulting or Advisory Role - Immunogen
Speakers' Bureau - AstraZeneca; GlaxoSmithKline
 
David Starks
Research Funding - Takeda (Inst)
 
Stephen Welch
Honoraria - Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - Amgen; Eisai
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; I-Mab (Inst); Immunogen; InxMed (Inst); Iovance Biotherapeutics; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; VBL Therapeutics; Verastem/Pharmacyclics
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - AADi; Alkermes; Artios; AstraZeneca; Bayer; Kadmon; Merck; Mersana; Novartis; Pfizer/EMD Serono; Repare Therapeutics; Tesaro; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); tesaro (Inst)
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; Arcus Biosciences; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; InxMed; Jazz Pharmaceuticals; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Takeda; Toray Industries; Umoja Biopharma; VBL Therapeutics; Verastem; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Immunogen (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - Alkermes; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro